← Human Trials & Peer-Reviewed Studies
New trial of progestin-primed ovarian stimulation using dydrogesterone versus a typical GnRH antagonist regimen in assisted reproductive technology
Plain-language guide to PMID 30069600 (2018): controlled clinical trial of HMG (Human Menopausal Gonadotropin) in 251 women.
Key Facts
- PMID
- 30069600
- Journal
- Archives of gynecology and obstetrics
- Year
- 2018
- Study type
- Controlled Clinical Trial
- Authors
- Iwami N et al. (7 authors)
- DOI
- 10.1007/s00404-018-4856-8
What This Study Did, in Plain Language
What Was Tested
This controlled clinical trial looks at HMG (Human Menopausal Gonadotropin).
To compare the clinical and ongoing pregnancy rates between a protocol using oral dydrogesterone with human menopausal gonadotropin (HMG) for progestin-primed ovarian stimulation (PPOS) and the typical gonadotropin-releasing hormone (GnRH) antagonist regimen in women undergoing controlled ovarian hyperstimulation (COH).
Who Took Part
According to the abstract, 251 women were involved.
The age groups tagged for this paper are adults, women only.
This was a prospective, controlled study of 251 women who underwent COH for in vitro fertilization between October 2016 and July 2017.
The patients were allocated alternately into two groups: a dydrogesterone protocol (study group) and a GnRH antagonist protocol (control group).
How the Study Was Run
In both groups, all high-quality embryos were cryopreserved for later transfer.
The primary outcome was the ongoing pregnancy rate at 12 weeks per frozen-thawed embryo transfer (FET) and the secondary outcome was the clinical pregnancy rate.
What Was Measured
The subject headings attached to it are Cryopreservation, Dydrogesterone, Embryo Transfer, Fertilization in Vitro, Gonadotropin-Releasing Hormone, Hormone Antagonists and Luteinizing Hormone.
The authors tagged it with the keywords Controlled ovarian stimulation, GnRH antagonist, Premature LH surge and Progestin-primed ovarian stimulation.
What This Means in Plain Language
This is a controlled clinical trial of HMG (Human Menopausal Gonadotropin) in 251 women.
The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2018 (Archives of gynecology and obstetrics), a journal based in Germany.
More context: the HMG (Human Menopausal Gonadotropin) compound page, all human trials.
Our Notes on the Compound
HMG (Human Menopausal Gonadotropin): Menotropins: a glycoprotein preparation that supplies follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.